UNSPSC 51162747: Xylometazoline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WPY40FTH8K, chemically known as 2-imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)- but more generally known as xylometazoline, which bears US NIH Compound Identifier 5709. European Medicines Agency schedules Xylometazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00122MIG.

UNSPSC 51162747 Xylometazoline is a Commodity code that covers pharmaceutical products, specifically decongestant nasal sprays and related parenteral medications, but recent state and local solicitations under this code reflect a broader procurement pattern focused on parenteral solutions, intravenous products, and emergency medical supplies rather than xylometazoline specifically. State and local governments procure these pharmaceutical products primarily through correctional health systems, county public health departments, and community health agencies to support healthcare delivery to incarcerated populations and community health initiatives. The Washington State Department of Corrections RFQ RFQQK13020 for parenteral products illustrates the scope: procurement of total parenteral nutrition solutions, intravenous solutions, and controlled substances for medically necessary healthcare, with strict delivery windows (24 hours for PN bags, 8 hours for other parenteral products) and documentation of experience in IV preparation and patient lab monitoring. Issuing bodies include state corrections departments and county health agencies; set-asides appear when state law applies, as demonstrated by Washington's Chapter 39.19 RCW requirements for minority and women-owned business utilization with aspirational 5% Small and Diverse Business Goals.

Recent activity centers on Washington and Florida. The Washington State Department of Corrections sought parenteral products for eight facilities across three regions (West, Central, and East) with an initial contract term from November 26, 2026 through June 30, 2030, planning to select up to three contractors per region, with response due October 7, 2026. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, though the posting date and response deadline in the source (July 2023) appear inconsistent with the post date of June 2026. Both solicitations require E-Verify compliance, drug-free workplace certification, and commercial general liability insurance; the Washington opportunity specifically mandates Washington State business licensure and Washington State Patrol NCIC clearance for all service-delivery personnel.